Halozyme Therapeutics

Historical price data

Halozyme Therapeutics has established itself as a dominant force in subcutaneous drug delivery through its validated ENHANZE® technology platform. The company's strategy successfully combines high-margin royalty and milestone revenue from over a dozen partnerships with leading pharma companies (including Roche, Takeda, and Pfizer) with direct sales from its commercial products, HYLENEX® and XYOSTED®. This dual business model provides diversified revenue streams and leverages a single, scalable platform technology to reduce treatment burden and improve patient outcomes across multiple therapeutic areas. Halozyme's commercial validation and expanding partnership pipeline position it for sustained growth as the industry shifts towards convenient, patient-centric administration.

ENHANZE® drug delivery platform utilizing recombinant human hyaluronidase (rHuPH20) to enable rapid subcutaneous delivery of large-volume biologics, converting intravenous infusions to minutes-long injections.

Halozyme holds a first-mover advantage with the only broadly validated recombinant human hyaluronidase platform. Competition includes alternative formulation strategies and delivery devices, but the clinical and commercial validation of ENHANZE® across multiple therapeutics and partners creates a significant barrier to entry. Its primary competition is often the IV formulation of its partners' own drugs.